Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma

Abstract

Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs)— either as monotherapy or in combination with other ICIs or chemotherapy—have demonstrated benefits in first-line therapy for advanced disease, the neoadjuvant and adjuvant settings, as well as in additional thoracic malignancies such as small-cell lung cancer (SCLC) and mesothelioma. Challenging questions remain, however, on topics including therapy selection, appropriate biomarker-based identification of patients who may derive benefit, the use of immunotherapy in special populations such as people with autoimmune disorders, and toxicity management. Patient and caregiver education and support for quality of life (QOL) is also important to attain maximal benefit with immunotherapy. To provide guidance to the oncology community on these and other important concerns, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). This CPG represents an update to SITC’s 2018 publication on immunotherapy for the treatment of NSCLC, and is expanded to include recommendations on SCLC and mesothelioma. The Expert Panel drew on the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for lung cancer and mesothelioma, including diagnostic testing, treatment planning, immune-related adverse events, and patient QOL considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers using immunotherapy to treat patients with lung cancer or mesothelioma.

STopover captures spatial colocalization and interaction in the tumor microenvironment using topological analysis in spatial transcriptomics data

“…To assess the usefulness of the method in cancer tissues, STopover was applied to the human lung adenocarcinoma (ADC) Visium datasets. Lung cancer is one of the cancer types in which immunotherapy plays a crucial role in patient treatment 12 . First, reference single-cell data obtained from human lung cancer tissue 13 were integrated with spatial data using CellDART 14 to estimate the spatial distribution of the major cell types.…”

Optimizing molecular testing of lung cancer needle biopsy specimens: potential solutions from an interdisciplinary qualitative study

“…Although NGS may take several weeks to process, rapid EGFR testing workflows have been reported and allow treatment with EGFR -directed therapies within days, all without compromising NGS workflows [ 23 ]. Archiving tissue for future molecular testing was proposed as another potential solution; an important limitation to this approach is that tissues may lose antigenicity over time [ 2 , 45 ], and characteristics of advanced tumors may change after treatment [ 46 ].…”

Clinical spectrum of Chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of LC treatment

“…ILDs are a group of heterogeneous, diffuse parenchymal lung diseases with similar clinical manifestations and disease behaviors but variable causes, including occupational ILD, connective tissue disease (CTD)-ILD, drug-induced ILD, radiation pneumonitis, idiopathic interstitial pneumonia (IIP), etc. [ 11 ]. ILDs, especially idiopathic pulmonary fibrosis (IPF), are associated with an increased risk of LC.…”